NCT02424968View on ClinicalTrials.gov

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 3, 2020

Study Completion Date

April 30, 2021

Conditions
Acute Myeloid LeukemiaB-Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaHodgkin LymphomaMyelodysplastic SyndromeMyeloproliferative NeoplasmT-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Anti-Thymocyte Globulin

Given per standard institutional practice

DRUG

Cyclosporine

Given PO

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant

Undergo nonmyeloablative allogeneic HSCT

BIOLOGICAL

Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells

Receive CD8+ memory T-cells via IV

RADIATION

Total Nodal Irradiation

Undergo TLI

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Robert Lowsky

OTHER

NCT02424968 - CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter